Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?

Pulmonx Corporation (NASDAQ:LUNG) is one of the best stocks under $3 to invest in. On October 28, Lake Street lowered the firm’s price target on Pulmonx to $4 from $8 and kept a Buy rating on the shares.

The firm believes that Wall Street will view the return of former CEO Glen French and CFO Derrick Sung positively. The shares are attractive due to the vast clinical proof of concept of Zephyr valves, the strong market opportunity, and the new product pipeline.

Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In?

On the same day, Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Pulmonx and set a price target of $5.00. Additionally, John Young CFA from Canaccord Genuity maintained a Buy rating on Pulmonx, with a price target of $6.00.

Pulmonx Corporation (NASDAQ:LUNG) is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.

While we acknowledge the potential of LUNG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LUNG and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.